Apogee Therapeutics
Develops long-acting antibody therapies for atopic dermatitis, asthma, and other inflammatory diseases.
$135.02
After-hours close+0.06 (+0.04%)
At close$134.97(+0.00%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 119.18%Insiders 2.57%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 61.88M · Float 57.17M · 92.4% free float
Institutions13F, as of Jun 30, 2026
309 holders · 73.74M shares · 118 new positions · 202 increased · 70 reduced · 53 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| VR Adviser, LLC | 8.49M | 13.73% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 5.51M | 8.90% | +1.42M | Aug 7, 2026 |
| HBK Investments L P | 2.85M | 4.61% | +2.85Mnew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.57M | 4.16% | +70.0K | Aug 13, 2026 |
| FMR LLC | 2.49M | 4.03% | −6.77M | Aug 13, 2026 |
| State Street Corp | 2.30M | 3.71% | +134.8K | Aug 7, 2026 |
| Driehaus Capital Management LLC | 1.74M | 2.81% | −180.7K | Aug 14, 2026 |
| Goldman Sachs Group Inc | 1.69M | 2.74% | +1.04M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.80% | 10.29M | 13G | Apr 8, 2026 ↗ |
| FMR LLC | 15.00% | 6.91M | 13G | Aug 6, 2025 ↗ |
| Wellington Group Holdings LLPincl. Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP +1 more | 10.70% | 4.81M | 13G | Oct 4, 2024 ↗ |
| Tomas Kiselakincl. Fairmount Funds Management LLC, Peter Evan Harwin +1 more | 9.99% | 6.81M | 13D | Jun 23, 2026 ↗ |
| Wellington Management Group LLP | 8.70% | 4.75M | 13G | Feb 10, 2026 ↗ |
| BlackRock, Inc. | 5.50% | 2.52M | 13G | Jul 16, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Michael Thomas Henderson | director, officer: Chief Executive Officer | 920.9K | 1.49% | Jul 10, 2026 |
| Fairmount Funds Management LLC | director | 340.9K | 0.55% | Aug 11, 2026 |
| Carl Dambkowski | officer: Chief Medical Officer | 168.5K | 0.27% | Aug 7, 2026 |
| Jane Henderson | officer: Chief Financial Officer | 158.4K | 0.26% | Jul 24, 2026 |
4 people have not refiled in the last 18 months (1.83M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 5, 2026 | Carl Dambkowskiofficer: Chief Medical Officer | Sale | 5,500 | $134.17 | 168,498 |
| Jul 8, 2026 | Michael Thomas Hendersondirector, officer: Chief Executive Officer | Sale | 20,000 | $133.63 | 995,987 |
| Jul 1, 2026 | Carl Dambkowskiofficer: Chief Medical Officer | Sale | 5,500 | $132.74 | 177,873 |
| Jun 22, 2026 | Michael Thomas Hendersondirector, officer: Chief Executive Officer | Sale | 80,000 | $132.54 | 1,015,987 |
| Jun 22, 2026 | Carl Dambkowskiofficer: Chief Medical Officer | Sale | 26,400 | $132.60 | 179,248 |
| Jun 10, 2026 | Michael Thomas Hendersondirector, officer: Chief Executive Officer | Sale · 6 lots | 20,000 | $83.38 | 1,095,987 |
| Jun 3, 2026 | Carl Dambkowskiofficer: Chief Medical Officer | Sale | 5,500 | $78.71 | 205,648 |
| May 13, 2026 | Michael Thomas Hendersondirector, officer: Chief Executive Officer | Sale · 2 lots | 20,000 | $82.09 | 1,115,987 |
| May 6, 2026 | Carl Dambkowskiofficer: Chief Medical Officer | Sale · 2 lots | 5,500 | $84.14 | 207,023 |
| May 1, 2026 | Jane Hendersonofficer: Chief Financial Officer | Sale · 3 lots | 2,000 | $82.04 | 173,371 |
CongressHouse and Senate disclosures
Not reported.